Corneal samples were homogenized as described by Brown et al.
20 After homogenization in 200 μL Tris-HCl (pH 7.4; 50 mM), containing 10 mM CaCl
2, 1% Triton X-100 and a cocktail of protease inhibitors, the samples were centrifuged at 9000 rpm at 4°C for 30 minutes. The concentrations of the total protein were measured with the bicinchoninic acid (BCA) protein assay.
21 Equal amounts of individual samples (12 μg) were mixed with 5 μL of 4× sample loading buffer (0.125 M Tris-HCl [pH 6.8], 4% SDS, 40% glycerol, and 0.02% bromphenol blue), containing β-mercaptoethanol, and boiled for 5 minutes. The samples and a prestained molecular mass marker (Bio-Rad, Cambridge, MA) were electrophoresed on 12% SDS gels and subsequently transferred to nitrocellulose membranes. The membranes were blocked for 30 minutes (Tris-buffered saline, containing 0.5% Tween 20, 3% nonfat milk, and 2% bovine serum albumin; Blotto; Santa Cruz Biotechnology, Santa, Cruz, CA) and then incubated for 2 hours at room temperature with the specific primary antibody, a polyclonal antibody directed to four fractions of the recombinant 50-kDa human heparanase that reacts with human and mouse Hpa1 heparanase. In Western blots, the antibody recognizes primarily the active form of the enzyme (50 kDa) and to a much lower extent the 65-kDa latent form (ImClone Systems, New York, NY). Samples without primary antibody treatment were processed as negative controls or treated with an irrelevant antibody of the same isotype or normal serum. Afterward, the blots were incubated with secondary antibody conjugated with horseradish peroxidase (0.5 μg/mL; Roche Diagnostics, Indianapolis, IN) at room temperature for 1 hour. Finally, the blots were developed by the chemiluminescence kit (Amersham, Arlington Heights, IL), and heparanase was visualized as dark bands.